Evaluation of vatiquinone drug-drug interaction potential in vitro and in a phase 1 clinical study with tolbutamide, a CYP2C9 substrate, and omeprazole, a CYP2C19 substrate, in healthy subjects

被引：0
|
作者：
Katsuyuki Murase
Lucy Lee
Jiyuan Ma
Rosemary Barrett
Martin Thoolen
机构：
[1] PTC Therapeutics,
[2] Inc.,undefined
来源：
European Journal of Clinical Pharmacology | 2022年 / 78卷
关键词：
Vatiquinone; Drug-drug interactions; Pharmacokinetics; CYP inhibition; Healthy volunteers;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1823 / 1831
页数：8
相关论文
共 50 条
  • [31] Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro
    Stage, Tore Bjerregaard
    Graff, Magnus
    Wong, Susan
    Rasmussen, Louise Ladebo
    Nielsen, Flemming
    Pottegard, Anton
    Brosen, Kim
    Kroetz, Deanna L.
    Khojasteh, Cyrus
    Damkier, Per
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (03) : 510 - 519
  • [32] Is the urinary metabolic ratio of flurbiprofen (probe drug for CYP2C9) affected by simultaneous phenotyping with dextromethorphan (CYP2D6) or omeprazole (CYP2C19)?
    Vogl, S.
    Schoenfelder, G.
    Lutz, W. K.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2015, 388 : S62 - S63
  • [33] Effects of CYP2C9*3 and CYP2C9*13 on Diclofenac Metabolism and Inhibition-based Drug-Drug Interactions
    Zi, Jing
    Liu, Duan
    Ma, Pingping
    Huang, He
    Zhu, Juanli
    Wei, Dongqing
    Yang, Jin
    Chen, Chao
    DRUG METABOLISM AND PHARMACOKINETICS, 2010, 25 (04) : 343 - 350
  • [34] Characterization of CYP2C19 and CYP2C9 from human liver:: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations
    Lasker, JM
    Wester, MR
    Aramsombatdee, E
    Raucy, JL
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1998, 353 (01) : 16 - 28
  • [35] Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients
    Katrijn Bogman
    Mariabeth Silkey
    Siew Pheng Chan
    Brian Tomlinson
    Cornelia Weber
    European Journal of Clinical Pharmacology, 2010, 66 : 1005 - 1015
  • [36] Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine
    Green, Bruce
    Crauwels, Herta
    Kakuda, Thomas N.
    Vanveggel, Simon
    Brochot, Anne
    CLINICAL PHARMACOKINETICS, 2017, 56 (05) : 525 - 536
  • [37] Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine
    Bruce Green
    Herta Crauwels
    Thomas N. Kakuda
    Simon Vanveggel
    Anne Brochot
    Clinical Pharmacokinetics, 2017, 56 : 525 - 536
  • [38] Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients
    Bogman, Katrijn
    Silkey, Mariabeth
    Chan, Siew Pheng
    Tomlinson, Brian
    Weber, Cornelia
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (10) : 1005 - 1015
  • [39] Implication of genetic polymorphisms in CYP2C9 and CYP2C19 on drug metabolism in isolated cryopreserved human hepatocytes
    Tolondo, Roberto
    Brown, Caitlin
    Heyward, Scott
    DRUG METABOLISM REVIEWS, 2010, 42 : 262 - 262
  • [40] Evaluation of CYP3A, CYP2C9 and CYP2C19 enzyme induction in very early phase 1 studies.
    Frye, R
    Ferry, S
    Yeh, S
    Sundaresan, PR
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P55 - P55
12345